Clinical Trial Update: Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating tarlatamab vs standard-of-care chemotherapy in pre-treated advanced pulmonary or gastroenteropancreatic poorly differentiated neuroendo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Carcinoma
• Pulmonary Neuroendocrine Carcinoma

Drugs mentioned

• Tarlatamab

Snippet

Sponsor: Intergroupe Francophone de Cancerologie Thoracique | Conditions: Neuroendocrine Carcinoma | Phase 3 | Status: RECRUITING